SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is seeing intense retail frenzy and extreme volatility, driven by investor scramble for exposure to private AI and space unicorns like Anthropic, OpenAI, and SpaceX. While some traders are riding the momentum and betting on further gains, community sentiment is heavily polarized due to concerns over its massive premium to net asset value, a restricted share lockup preventing easy selling, and comparisons to other vehicles like $ORBS or $DXYZ.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors debate the impact of a bipartisan Senate bill aimed at restricting sports betting contracts on prediction market platforms. While some community members view the legislation as a competitive win that reinforces the company's regulatory moat, others remain skeptical, citing continued insider selling and broader sector volatility.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing positive market sentiment driven by the announced departure of a key FDA official, which investors perceive as a catalyst for a more favorable regulatory environment for its gene therapy pipeline. Community members are actively discussing the stock's significant short interest and the anticipation of upcoming clinical data readouts, fueling speculation about potential institutional accumulation and short-term volatility.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing extreme volatility and intense community debate following a provocative short report from Culper Research that alleges aggressive channel stuffing practices. While management has issued a rebuttal calling the assertions misleading and false, investors remain deeply divided, with many aggressively adding to their positions in anticipation of a rebound while others express frustration over the perceived weakness of the response and the resulting share price pressure.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing intense volatility and bearish sentiment as investors react to a recent reverse stock split, which has sparked widespread frustration regarding the company's lack of transparent guidance and perceived mismanagement. The community is actively debating whether the split will genuinely improve institutional appeal or if it is merely a precursor to further dilution, with many retail holders expressing skepticism about the company's long-term viability under current leadership.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant momentum and heavy trading volume as investors react to the company's expanding role in NASA's updated Artemis lunar base infrastructure plans and anticipation of upcoming contract awards. The community is actively debating the stock's volatility and growth prospects, with many bulls focusing on the company's long-term potential as a key service provider for sustained lunar operations.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant attention as traders view it as a primary proxy for exposure to major private tech players, particularly SpaceX and Anthropic. The community is actively debating the fund's heavy premium relative to its net asset value, with some retail investors aggressively accumulating shares in anticipation of a potential SpaceX IPO while others caution against the risk of dilution and overvaluation.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened investor scrutiny and volatility as community sentiment grapples with aggressive capital expenditure plans, competitive pressures in the AI space, and broader geopolitical tensions impacting the tech sector. While some traders are actively shorting the stock, citing technical weakness compared to other 'Mag 7' peers, others are highlighting the company's long-term potential in AI infrastructure and cloud growth as a reason to buy the dip.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant market activity as investors weigh the potential catalyst of a SpaceX IPO against the companys own upcoming BlueBird 7 launch. The community remains heavily divided between long-term holders betting on institutional partnerships and the broader space sector growth, and skeptical traders voicing frustration over launch delays and insider activity.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is experiencing heightened momentum as investors react to a newly expanded U.S. Naval research deal and a broader speculative rotation into the space supply chain. The community is actively debating the stock's long-term valuation relative to peers, with many focusing on institutional accumulation and upcoming catalyst events in the space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck & Co., Inc. (NYSE:MRK) Shares Acquired Rep. Josh Gottheimer

Representative Josh Gottheimer (Democratic-New Jersey) recently bought shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on March 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on February 4th. The trade occurred in the Repre...

<ul class="summary-bullets"><li>The acquisition centers on Terns’ oral CML treatment, TERN-701, currently in mid-stage clinical trials.</li><li>TERN-701 received orphan drug designation in 2024, highlighting its potential for the treatment of rare leukemias.</li><li>The deal is expected to be completed in the second quarter of 2026.</li></ul>Merck &amp; Co. Inc. (MRK) has struck a multibillion-dollar deal to expand its oncology pipeline, agreeing to acquire clinical-stage biotech firm Terns Pharmaceuticals Inc. (TERN) for $53 per share in cash, at an approximate $6.7 billion valuation.&nbsp;The offer represents a 6% premium over Terns’ closing price as of Tuesday.&nbsp;<h2 class="st-heading-2">Focus On Cancer Drug Development</h2>Central to the acquisition is Terns’ experimental therapy, TERN-701, an oral treatment targeting specific mutations linked to chronic myeloid leukemia. The drug candidate is currently under evaluation in mid-stage clinical trials.&nbsp;<blockquote>“The acquisition of Terns builds on our growing presence in hematology with TERN-701, a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia.”-Robert M. Davis, Chairman and CEO, Merck</blockquote>Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/TERN">Terns Pharmaceuticals’ stock</a> traded over 4% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Regulatory Momentum And Trial Outcomes</h2>U.S. regulators granted TERN-701 orphan drug status in 2024, signaling its potential as a treatment for a rare form of leukemia. Early trial findings have shown encouraging outcomes, including meaningful molecular responses within months of treatment.“Based on early clinical evidence, TERN-701, a novel allosteric BCR::ABL1 inhibitor, may have the potential to provide a meaningfully differentiated option for certain patients living with CML,” said Dean Y. Li, President, Merck Research Laboratories.The companies anticipate finalizing the acquisition deal in the second quarter of 2026.MRK stock has gained over 10% year to date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sandisk-commits-1-b-to-nanya-in-strategic-chip-sector-bet/cZ3YNwZRISI">Sandisk Commits $1B To Nanya In Strategic Chip Sector Bet</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck To Acquire Terns In $6.7B Deal – Signaling Fresh Push In Competitive Cancer Drug Race 

At the core of the deal is Terns’ investigational drug TERN-701, an oral therapy designed to address mutations associated with chronic myeloid leukemia.

Equity

At the core of the deal is Terns’ investigational drug TERN-701, an oral therapy designed to address mutations associated with chronic myeloid leukemia.


Pensionfund Sabic Makes New $3.05 Million Investment in Merck & Co., Inc. $MRK

Pensionfund Sabic purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange...

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (Terns) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies...

SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff

SLS vs TERN Stock - Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

E. Ohman J or Asset Management AB Purchases Shares of 88,457 Merck & Co., Inc. $MRK

E. Ohman J or Asset Management AB acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the...

Contravisory Investment Management Inc. Purchases 70,550 Shares of Merck & Co., Inc. $MRK

Contravisory Investment Management Inc. boosted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 19,435.3% in the fourth quarter, according to the company in its most recent...

Central Bank & Trust Co. Sells 13,216 Shares of Merck & Co., Inc. $MRK

Central Bank & Trust Co. decreased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 31.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,470 shares of the compa...

Avanza Fonder AB Purchases 25,344 Shares of Merck & Co., Inc. $MRK

Avanza Fonder AB increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 289,720 shares of the company's stock after buying an addit...

Merck (MRK) Exceeds Market Returns: Some Facts to Consider

Merck (MRK) reached $115.68 at the closing of the latest trading day, reflecting a +1.31% change compared to its last close.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.51	--	--	N/A
Q4 '25	$2.01	$2.04	1.43%	BEAT
Q3 '25	$2.35	$2.58	9.90%	BEAT
Q2 '25	$2.02	$2.13	5.40%	BEAT
Q1 '25	$2.13	$2.22	3.99%	BEAT

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest MRK News

MRKMerck & Co Inc